These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32102342)

  • 21. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
    Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
    Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
    [No Abstract]   [Full Text] [Related]  

  • 23. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.
    Masetti R; Biagi C; Zama D; Vendemini F; Martoni A; Morello W; Gasperini P; Pession A
    Adv Ther; 2012 Sep; 29(9):747-62. PubMed ID: 22941525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunocombination therapy for high-risk neuroblastoma.
    Kroesen M; Lindau D; Hoogerbrugge P; Adema GJ
    Immunotherapy; 2012 Feb; 4(2):163-74. PubMed ID: 22394368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
    Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
    Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.
    Wang W; Xia X; Wu S; Guo M; Lie P; He J
    Am J Reprod Immunol; 2018 Jun; 79(6):e12793. PubMed ID: 29288509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
    Szychot E; Peregud-Pogorzelski J; Wawryków P; Brodkiewicz A
    Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1001-1004. PubMed ID: 27708204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.
    Vanichapol T; Chutipongtanate S; Anurathapan U; Hongeng S
    Biomed Res Int; 2018; 2018():1812535. PubMed ID: 29682521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
    Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
    Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
    Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroblastoma: Therapeutic strategies for a clinical enigma.
    Modak S; Cheung NK
    Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
    Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
    Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
    Greenwood K; Foster JH
    Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.